Chu lists the many appearances in Cusk’s fiction of women who want to be men and who hate themselves for this secret desire, ...

Copilot in OneDrive is a great tool for summarizing and comparing files, extracting key information, and generating FAQs—all ...

All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...

Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody ...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

The max poster file size is 6MB. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. All submitted posters will be reviewed, and ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...

from 12:30 PM to 1:30 PM PDT In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: "Integrating a Different Mechanism of Action, a different Class of ...

today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

The poster presentations will include preclinical safety and efficacy results, highlighting STRO-004's significant anti-tumor activity and safety profile. Sutro's CEO, Jane Chung, expressed ...